Table of Contents
What is Ketamine?
Ketamine is a medication that was developed in the mid-1960’s as an anaesthetic, helping to numb pain during medical procedures. Ketamine can be given in different ways, such as through a needle in a vein, or as a pill, liquid, or spray.
In recent years, ketamine has been studied as a treatment for depression. While it’s not the first choice of treatment for depression, researchers are continuing to study the drug to see how effective it might be.
Medical use of ketamine is known to cause some side effects, such as hallucinations, bad dreams, drowsiness or dizziness, blurred vision, restlessness, or vomiting. It can also increase blood pressure and heart rate.
Effects of ketamine abuse on the urinary tract
Some people use ketamine at parties or social gatherings to purposely experience hallucinations and altered perceptions. It is also sometimes used illegally by people to manage chronic pain conditions. While ketamine abuse is not very common among the general population, its recreational use has increased in recent years, especially among teenagers and young adults.
Although young people may think the short-term effects of ketamine, such being in a dream-like state or having out-of-body experiences are harmless, ketamine is addictive and dangerous.
A “bad trip” can cause a frightening sensation of total dissociation that has been likened to a near-death experience. Since ketamine is tasteless and odourless, it can be added to drinks without the intended victim knowing and used as a “date rape” drug.
Long-term use of ketamine can cause significant issues with brain function, such as amnesia, flashbacks, memory problems, and anxiety. It can also lead to bladder complications, like damage to the urinary tract, bladder inflammation, an increased need to urinate, blood in the urine, incontinence and pain passing urine.
When taken in high amounts, ketamine can affect the upper urinary tract, leading to problems with how the kidneys work.
The exact number of ketamine abusers experiencing urinary tract problems is not known for sure, but studies suggest that between 25% and 33% of intensive ketamine abusers may be affected.
Treatment for ketamine abuse
It is crucial for ketamine users to quit the drug completely, but quitting can be difficult due to its addictive nature and pain-relieving effects.
Treatment in the early stages focuses on managing pain and bladder symptoms with medications. Talking therapy is also offered to help overcome addiction and increase the chances of recovery.
Many people can recover from their symptoms if treatment is started early. However, in some cases, permanent damage may result in the need for different treatments, like having liquid drugs inserted directly into the bladder (called a bladder wash) or injections of botulinum toxin into the bladder wall. In some cases, an operation called electrocoagulation is needed to repair the damage inside the bladder.
In severe cases, a partial cystectomy (surgically removing part of the bladder) or an operation to make the bladder bigger may be needed. In rare situations, when pain makes it impossible to avoid drug abuse, the entire bladder may need to be removed.
Awareness
It’s crucial to be aware of the risks associated with ketamine abuse, as it can be harmful to both physical and mental health. If you are struggling with ketamine abuse, or you suspect your child or someone you know is struggling, seek professional help and support as soon as possible.
References
- Jhang JF, Birder LA, Kuo HC. Pathophysiology, clinical presentation, and management of ketamine-induced cystitis. Tzu Chi Med J. 2023 Jun 13;35(3):205-212. doi: 10.4103/tcmj.tcmj_94_23. PMID: 37545795; PMCID: PMC10399845. (open access)
- Vizgan G, Huamán M, Rychik K, Edeson M, Blaivas JG. Ketamine-induced uropathy: A narrative systemic review of surgical outcomes of reconstructive surgery. BJUI Compass. 2023 Apr 19;4(4):377-384. doi: 10.1002/bco2.239. PMID: 37334018; PMCID: PMC10268589. (open access)
- Zhou J, Scott C, Miab ZR, Lehmann C. Current approaches for the treatment of ketamine-induced cystitis. Neurourol Urodyn. 2023 Mar;42(3):680-689. doi: 10.1002/nau.25148. Epub 2023 Feb 13. PMID: 36780131.
- Orhurhu VJ, Vashisht R, Claus LE, Cohen SP. Ketamine Toxicity. 2023 Jan 30. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 31082131. (Free at https://www.ncbi.nlm.nih.gov/books/NBK541087/)
- Chan EOT, Chan VWS, Tang TST, Cheung V, Wong MCS, Yee CH, Ng CF, Teoh JYC. Systematic review and meta-analysis of ketamine-associated uropathy. Hong Kong Med J. 2022 Dec;28(6):466-474. doi: 10.12809/hkmj209194. Epub 2022 Dec 5. PMID: 36464318. (open access)
- Anderson DJ, Zhou J, Cao D, McDonald M, Guenther M, Hasoon J, Viswanath O, Kaye AD, Urits I. Ketamine-Induced Cystitis: A Comprehensive Review of the Urologic Effects of This Psychoactive Drug. Health Psychol Res. 2022 Sep 15;10(3):38247. doi: 10.52965/001c.38247. PMID: 36118982; PMCID: PMC9476224. (open access)
- Lamers G, Van Dyck J, Schapmans S, De Coster K, Mortier D, Zabegalina N. Ketamine-induced uropathy: A diagnostic pitfall in an increasing healthcare issue in youngsters. Urol Case Rep. 2022 Feb 1;42:102019. doi: 10.1016/j.eucr.2022.102019. PMID: 35530548; PMCID: PMC9073215. (open access)
- Chen CL, Wu ST, Cha TL, Sun GH, Meng E. Molecular Pathophysiology and Potential Therapeutic Strategies of Ketamine-Related Cystitis. Biology (Basel). 2022 Mar 24;11(4):502. doi: 10.3390/biology11040502. PMID: 35453701; PMCID: PMC9029571. (open access)
- Chen CL, Wu ST, Cha TL, Sun GH, Meng E. Molecular Pathophysiology and Potential Therapeutic Strategies of Ketamine-Related Cystitis. Biology (Basel). 2022 Mar 24;11(4):502. doi: 10.3390/biology11040502. PMID: 35453701; PMCID: PMC9029571.
- Ou SH, Wu LY, Chen HY, Huang CW, Hsu CY, Chen CL, Chou KJ, Fang HC, Lee PT. Risk of Renal Function Decline in Patients with Ketamine-Associated Uropathy. Int J Environ Res Public Health. 2020 Oct 4;17(19):7260. doi: 10.3390/ijerph17197260. PMID: 33020445; PMCID: PMC7579140. (open access)
- Castellani D, Pirola GM, Gubbiotti M, Rubilotta E, Gudaru K, Gregori A, Dellabella M. What urologists need to know about ketamine-induced uropathy: A systematic review. Neurourol Urodyn. 2020 Apr;39(4):1049-1062. doi: 10.1002/nau.24341. Epub 2020 Mar 25. PMID: 32212278.
- Jhang JF, Wang HJ, Hsu YH, Birder LA, Kuo HC. Upregulation of neurotrophins and transforming growth factor-β expression in the bladder may lead to nerve hyperplasia and fibrosis in patients with severe ketamine-associated cystitis. Neurourol Urodyn. 2019 Nov;38(8):2303-2310. doi: 10.1002/nau.24139. Epub 2019 Aug 21. PMID: 31433072.
- Jhang JF, Birder LA, Chancellor MB, Kuo HC. Patient characteristics for different therapeutic strategies in the management ketamine cystitis. Neurourol Urodyn. 2017 Mar;36(3):687-691. doi: 10.1002/nau.22996. Epub 2016 Mar 21.
- Yek J, Sundaram P, Aydin H, Kuo T, Ng LG. The clinical presentation and diagnosis of ketamine-associated urinary tract dysfunction in Singapore. Singapore Med J. 2015 Dec;56(12):660-4; quiz 665. doi: 10.11622/smedj.2015185. Free PMC Article.
- Myers FA Jr, Bluth MH, Cheung WW. Ketamine: A Cause of Urinary Tract Dysfunction. Clin Lab Med. 2016 Dec;36(4):721-744. doi: 10.1016/j.cll.2016.07.008.
- Sassano-Higgins S, Baron D, Juarez G, Esmaili N, Gold M. A review of ketamine abuse and diversion. Depress Anxiety. 2016 Aug;33(8):718-27. doi: 10.1002/da.22536. Epub 2016 Jun 22.